Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q2 2020 · 10-Q
Revenue$2.00K$2.00K−99.7% vs Q2 2019 Net Income-$57.95M-$57.95MN/M vs Q2 2019 EPS Diluted-$0.08-$0.08— vs Q2 2019 Operating Income-$7,436,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-371800.0%−370657.7 pt vs Q2 2019
Net margin-2897600.0%−2897637.7 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 10, 2020 · 41 d after period end